

Form TO-1449

**LIST OF PATENTS AND  
PUBLICATIONS FOR  
APPLICANT'S INFORMATION  
DISCLOSURE STATEMENT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete If Known**

Application Number	10/776,584
Filing Date	February 1, 2004
First Named Inventor	Matthew C.T. FYFE
Art Unit	<del>Unassigned</del> 1626
Examiner Name	<del>Unassigned</del> SAEED
Attorney Docket No.	NC-10001

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION OR ISSUE DATE	INVENTOR	CLASS/ SUBCLASS
KS	A1	6,320,050	11-20-2001	Bizzarro	
	A2	6,353,111	03-05-2002	Corbett	
	A3	6,369,232	04-09-2002	Sidduri	
	A4	6,384,220	05-07-2002	Corbett	
	A5	6,388,071	05-14-2002	Mahaney	
	A6	6,388,088	05-14-2002	Siddori	
	A7	6,433,188	08-13-2002	Corbett	
	A8	6,441,180	08-27-2002	Sidduri	
	A9	6,441,184	08-27-2002	Corbett	
	A10	6,448,399	09-10-2002	Corbett	
	A11	6,482,951	11-19-2002	Guertin	
	A12	6,486,184	11-26-2002	Kester	
KS	A13	6,489,485	12-03-2002	Bizzarro	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION DATE	APPLICANT	COUNTRY
KS	B1	WO 04/050645	06-17-2004	Novartis AG	PCT
	B2	WO 00/058293	10-05-2000	F. Hoffman-La Roche	PCT
	B3	WO 01/044216	06-21-2001	F. Hoffman-La Roche	PCT
	B4	WO 01/083465	11-08-2001	F. Hoffman-La Roche	PCT
	B5	WO 01/083478	11-08-2001	F. Hoffman-La Roche	PCT
	B6	WO 01/085706	11-15-2001	F. Hoffman-La Roche	PCT
	B7	WO 01/085707	11-15-2001	F. Hoffman-La Roche	PCT
	B8	WO 02/008209	01-31-2002	F. Hoffman-La Roche	PCT
	B9	WO 02/014312	02-21-2002	F. Hoffman-La Roche	PCT
	B10	WO 02/046173	06-13-2002	F. Hoffman-La Roche	PCT
	B11	WO 02/048106	06-20-2002	F. Hoffman-La Roche	PCT
	B12	WO 03/000262	01-03-2003	Astrazeneca AB	PCT
KS	B13	WO 03/000267	01-03-2003	Astrazeneca AB	PCT

EXAMINER INITIAL	REFERENCE DESIGNATION	OTHER ART (Include Author, Title, Date, Pages, etc.)
KS	C1	R.L. Printz et al., Ann. Rev. Nutrition, 13:463-496(1993)
KS	C2	Y.Liang et al., Biochem. J., 309:167-173(1995)
KS	C3	H.B.T. Christesen et al., Diabetes, 51:1240-1246(2002)
KS	C4	Printout of Delphion Abstract for WO 03/97824

EXAMINER /Kamal Saeed/

Date Considered: 03/04/2007

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449				<b>Complete If Known</b>	
<b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b> (Use as many sheets as necessary)				Application Number	10/776,584
				Filing Date	February 1, 2004
				First Named Inventor	Matthew C.T. FYFE
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket No.	NC-10001

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION OR ISSUE DATE	INVENTOR	CLASS/SUBCLASS
KS	A14	6,610,846	08-26-2003	Bizzarro	
KS	A15	2003/0219887	11-27-2003	Corbett	

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION DATE	APPLICANT	COUNTRY
KS	B14	WO 03/015774	02-27-2003	Astrazeneca AB	PCT
KS	B15	WO 03/047626	06-12-2003	Novo Nordisk	PCT
KS	B16	WO 03/055482	07-10-2003	Novo Nordisk	PCT
KS	B17	WO 03/080585	10-02-2003	Banyu Pharm.	PCT
KS	B18	WO 03/095438	11-20-2003	F. Hoffman-La Roche	PCT
KS	B19	WO 03/097824	11-27-2003	Banyu Pharm.	PCT
KS	B20	WO 04/002481	01-08-2004	Novo Nordisk	PCT

EXAMINER INITIAL	REFERENCE DESIGNATION	OTHER ART (Include Author, Title, Date, Pages, etc.)
KS	C5	Printout of Delphion Abstract for WO 03/080585

EXAMINER	/Kamal Saeed/	Date Considered: 03/04/2007
----------	---------------	-----------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.